European Equities Traded in the US as American Depositary Receipts Down in Friday Trading, Up for Week

MT Newswires Live
Oct 17

European equities traded in the US as American depositary receipts were tracking lower late Friday morning, declining 0.5% to 1,570.76 on the S&P Europe Select ADR Index, which is up 1% for the week.

From continental Europe, the gainers were led by consumer goods giant Unilever (UL) and internet advertising firm Criteo (CRTO), which rose 1.7% and 1.5% respectively. They were followed by oil and gas company TotalEnergies (TTE) and biopharmaceutical company DBV Technologies (DBVT), which were up 1.3% and 0.2% respectively.

The decliners from continental Europe were led by biotech firm Evaxion (EVAX) and biopharmaceutical company Cellectis (CLLS), which shed 27.4% and 10.8% respectively. They were followed by pharmaceutical company Novo Nordisk (NVO) and medical device manufacturer EDAP TMS (EDAP), which lost 4.1% and 2% respectively.

From the UK and Ireland, the gainers were led by educational publisher Pearson (PSO), which advanced 2.8%, followed by hospitality company InterContinental Hotels Group (IHG) and biopharmaceutical company Akari Therapeutics (AKTX), which rose 1.3% each.

The decliners from the UK and Ireland were led by biopharmaceutical companies Adaptimmune Therapeutics (ADAP) and Bicycle Therapeutics (BCYC), which dropped 7.5% and 5.3% respectively. They were followed by biotech firm Autolus Therapeutics and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which were down 5% and 3.8% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10